Brokers Set Expectations for LXEO Q1 Earnings

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Lexeo Therapeutics in a research note issued to investors on Monday, March 24th. Leerink Partnrs analyst M. Foroohar anticipates that the company will earn ($0.80) per share for the quarter. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics’ Q2 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.79) EPS and Q4 2025 earnings at ($0.79) EPS.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.09.

LXEO has been the topic of several other reports. Leerink Partners lowered their price target on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a report on Monday. HC Wainwright restated a “buy” rating and issued a $23.00 price objective on shares of Lexeo Therapeutics in a report on Wednesday. Chardan Capital reiterated a “buy” rating and issued a $25.00 target price on shares of Lexeo Therapeutics in a research note on Tuesday. Finally, Royal Bank of Canada cut their price target on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Lexeo Therapeutics has a consensus rating of “Buy” and a consensus price target of $22.80.

Lexeo Therapeutics Stock Up 3.0 %

LXEO stock opened at $4.11 on Wednesday. The firm has a 50 day simple moving average of $4.07 and a 200 day simple moving average of $6.63. The firm has a market cap of $135.90 million, a PE ratio of -1.30 and a beta of 3.85. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. Lexeo Therapeutics has a 12 month low of $2.32 and a 12 month high of $19.50.

Institutional Trading of Lexeo Therapeutics

A number of institutional investors have recently modified their holdings of LXEO. Geode Capital Management LLC boosted its position in Lexeo Therapeutics by 86.5% during the third quarter. Geode Capital Management LLC now owns 553,247 shares of the company’s stock valued at $5,003,000 after purchasing an additional 256,635 shares during the last quarter. State Street Corp increased its position in Lexeo Therapeutics by 29.4% during the third quarter. State Street Corp now owns 253,946 shares of the company’s stock worth $2,296,000 after buying an additional 57,674 shares during the last quarter. Frazier Life Sciences Management L.P. bought a new stake in Lexeo Therapeutics in the third quarter valued at approximately $11,307,000. Barclays PLC lifted its position in shares of Lexeo Therapeutics by 162.2% in the third quarter. Barclays PLC now owns 50,210 shares of the company’s stock valued at $454,000 after buying an additional 31,057 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its stake in shares of Lexeo Therapeutics by 18.9% during the 3rd quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company’s stock worth $33,997,000 after acquiring an additional 599,203 shares during the period. 60.67% of the stock is currently owned by institutional investors.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.